PURPOSE: HMGI-C (High Mobility Group protein Isoform I-C) protein is a member of the high-mobility group AT-hook (HMGA) family of small non-histone chromosomal protein that can modulate transcription of an ample number of genes. Genome-wide studies revealed up regulation of the HMGI-C gene in many human cancers. We suggested that HMGI-C might play a critical role in the progression and migration of various tumors. However, the exact role of HMGI-C in breast adenocarcinoma has not been cleared. METHODS: The cells were transfected with siRNAs using transfection reagent. Relative HMGI-C mRNA and protein levels were measured by quantitative real-time PCR and Western blotting, respectively. The cytotoxic effects of HMGI-C siRNA, Paclitaxel alone and combination on breast adenocarcinoma cells were determined using MTT assay. The migration after treatment by HMGI-C siRNA, Paclitaxel alone and combination were detected by wound-healing respectively. RESULTS: HMGI-C siRNA significantly reduced both mRNA and protein expression levels in a 48 hours after transfection and dose dependent manner. We observed that the knockdown of HMGI-C led to the significant reduced cell viability and inhibited cells migration in MDA-MB-468 cells in vitro. CONCLUSION: These results propose that HMGI-C silencing and Paclitaxel treatment alone can inhibit the proliferation and migration significantly, furthermore, synergic effect of HMGI-C siRNA and Paclitaxel showed higher inhibition compared to mono treatment. Taken together, HMGI-C could be used as a promising therapeutic agent in the treatment of human breast adenocarcinoma. Therefore HMGI-C siRNA may be an effective adjuvant in human breast adenocarcinoma.
PURPOSE:HMGI-C (High Mobility Group protein Isoform I-C) protein is a member of the high-mobility group AT-hook (HMGA) family of small non-histone chromosomal protein that can modulate transcription of an ample number of genes. Genome-wide studies revealed up regulation of the HMGI-C gene in many humancancers. We suggested that HMGI-C might play a critical role in the progression and migration of various tumors. However, the exact role of HMGI-C in breast adenocarcinoma has not been cleared. METHODS: The cells were transfected with siRNAs using transfection reagent. Relative HMGI-C mRNA and protein levels were measured by quantitative real-time PCR and Western blotting, respectively. The cytotoxic effects of HMGI-C siRNA, Paclitaxel alone and combination on breast adenocarcinoma cells were determined using MTT assay. The migration after treatment by HMGI-C siRNA, Paclitaxel alone and combination were detected by wound-healing respectively. RESULTS:HMGI-C siRNA significantly reduced both mRNA and protein expression levels in a 48 hours after transfection and dose dependent manner. We observed that the knockdown of HMGI-C led to the significant reduced cell viability and inhibited cells migration in MDA-MB-468 cells in vitro. CONCLUSION: These results propose that HMGI-C silencing and Paclitaxel treatment alone can inhibit the proliferation and migration significantly, furthermore, synergic effect of HMGI-C siRNA and Paclitaxel showed higher inhibition compared to mono treatment. Taken together, HMGI-C could be used as a promising therapeutic agent in the treatment of humanbreast adenocarcinoma. Therefore HMGI-C siRNA may be an effective adjuvant in humanbreast adenocarcinoma.
Entities:
Keywords:
Breast adenocarcinoma; HMGI-C (High mobility group protein isoform I-C); Paclitaxel; Small interference RNA (siRNA)
Authors: N Montazami; M Kheir Andish; J Majidi; M Yousefi; B Yousefi; L Mohamadnejad; D Shanebandi; M A Estiar; V Khaze; B Mansoori; E Baghbani; B Baradaran Journal: Cell Mol Biol (Noisy-le-grand) Date: 2015-05-28 Impact factor: 1.770
Authors: Masashi Narita; Masako Narita; Valery Krizhanovsky; Sabrina Nuñez; Agustin Chicas; Stephen A Hearn; Michael P Myers; Scott W Lowe Journal: Cell Date: 2006-08-11 Impact factor: 41.582
Authors: Kai-Yin Chau; Guidalberto Manfioletti; Kam-Wa Cheung-Chau; Alfredo Fusco; Nathalie Dhomen; Jane C Sowden; Tetsuo Sasabe; Shizuo Mukai; Santa Jeremy Ono Journal: Mol Med Date: 2003 May-Aug Impact factor: 6.354
Authors: Francescopaolo Di Cello; Joelle Hillion; Alexandra Hristov; Lisa J Wood; Mita Mukherjee; Andrew Schuldenfrei; Jeanne Kowalski; Raka Bhattacharya; Raheela Ashfaq; Linda M S Resar Journal: Mol Cancer Res Date: 2008-05 Impact factor: 5.852
Authors: Natalie Krahn; Markus Meier; Vu To; Evan P Booy; Kevin McEleney; Joe D O'Neil; Sean A McKenna; Trushar R Patel; Jörg Stetefeld Journal: Biophys J Date: 2017-12-19 Impact factor: 4.033
Authors: Saiedeh Razi Soofiyani; Akbar Mohammad Hoseini; Ali Mohammadi; Vahid Khaze Shahgoli; Behzad Baradaran; Mohammad Saeid Hejazi Journal: Adv Pharm Bull Date: 2017-12-31